Microscopic polyangiitis
MONDO:0019124Microscopic polyangiitis (MPA) is an inflammatory, necrotizing, systemic vasculitis that affects predominantly small vessels (i.e. small arteries, arterioles, capillaries, venules) in multiple organs.
Also known as: MPA, Micropolyangiitis, microscopic polyarteritis
36 clinical trials for this condition and its sub-types, 34 tagged with Microscopic polyangiitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control OngoingThis Phase 2 trial tests a one-time infusion of rapcabtagene autoleucel, a CAR-T cell therapy made from a patient's own immune cells, against standard treatments for severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). About 126 adults aged 18-7…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill aims to tame rare blood vessel disease
Disease control OngoingThis phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus stand…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThis study tests whether the drug avacopan can help children aged 6 to 18 with a rare autoimmune disease called ANCA-associated vasculitis, which causes inflammation of blood vessels. About 20 participants will receive avacopan alongside standard treatments like rituximab or cycl…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Phase 1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Phase 1/2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC